Semaglutide is a weekly GLP-1RA that has shown good efficacy in multiple trials.

Semaglutide is a weekly GLP-1RA that has shown good efficacy in multiple trials. For example, a 72 week phase II trial involving 320 MASH patients reported a MASH remission rate of up to 59% at the highest dose of 0.4 mg per day, compared to only 17% in the placebo group. However, the impact on fibrosis improvement is not consistent, and in some trials, there was no significant difference between semaglutide and placebo. Like liraglutide, gastrointestinal symptoms are the most common side effects, but are usually well tolerated.